| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 3 securities · passive | ||||||
|
Inventiva S.A.
13G/A
IVA · 46124U107
|
6.7% |
10/27/2026
Event 9/30/2026
|
||||
| Andera Partners | 6.7% | |||||
| BioDiscovery 6 FPCI | 6.7% | |||||
| Stephane Bergez | 6.7% | |||||
| Francois Xavier Mauron | 6.7% | |||||
|
Evommune, Inc.
13G/A
EVMN · 30054Y107
|
3.9% |
8/14/2026
Event 6/30/2026
|
||||
| Andera Partners | 3.9% | |||||
| BioDiscovery 6 FPCI | 3.9% | |||||
| Stephane Bergez | 3.9% | |||||
| Francois Xavier Mauron | 3.9% | |||||
|
Mineralys Therapeutics, Inc.
13G/A
MLYS · 603170101
|
4.2% |
8/14/2025
Event 6/30/2025
|
||||
| Andera Partners | 4.2% | |||||
| BioDiscovery 6 FPCI | 4.2% | |||||
| Stephane Bergez | 4.2% | |||||
| Francois Xavier Mauron | 4.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.